Greenwood Capital Associates LLC Has $11.05 Million Position in Eli Lilly and Company $LLY

Greenwood Capital Associates LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% in the first quarter, HoldingsChannel reports. The firm owned 12,014 shares of the company’s stock after selling 411 shares during the period. Eli Lilly and Company makes up about 1.2% of Greenwood Capital Associates LLC’s portfolio, making the stock its 16th largest position. Greenwood Capital Associates LLC’s holdings in Eli Lilly and Company were worth $11,050,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $25,000. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the period. Basso Capital Management L.P. bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $30,000. Finally, Maseco LLP boosted its holdings in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan and RBC both raised their price targets on Eli Lilly, reinforcing Wall Street’s view that the company still has meaningful upside despite its rich valuation.
• Positive Sentiment: LLY received another boost after its eczema treatment was approved in Canada, adding to the company’s growing non-obesity pipeline and supporting the bull case beyond weight-loss drugs. Article Title
• Positive Sentiment: Several articles highlighted Eli Lilly’s strong GLP-1 and obesity momentum, noting record highs and ongoing investor enthusiasm around Mounjaro, Zepbound, and the broader obesity market.
• Neutral Sentiment: Commentary pieces asked whether it is “too late” to buy LLY and whether the stock is too expensive, but these were largely opinion-driven and did not change the underlying business outlook.
• Neutral Sentiment: Healthcare stocks were broadly weaker late in the day, which may have added some sector-level drag on LLY even as company-specific news remained constructive. Article Title
• Negative Sentiment: Tampa General filed suit against Eli Lilly over pulled 340B discounts, creating a regulatory/legal overhang that could raise investor concerns about drug pricing and hospital reimbursement disputes. Article Title

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday. Truist Financial increased their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a report on Wednesday. Barclays lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Finally, HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price objective for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,255.89.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,218.76 on Thursday. The company has a market cap of $1.15 trillion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 1.54 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The business has a 50 day moving average price of $1,085.08 and a 200-day moving average price of $1,031.42. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.7 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.